文献速递腹部技术与安全MR

肝细胞癌动态增强MRI灌注定量:钆塞酸二钠与钆贝葡胺的比较

Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.
PubMed 文献 · Eur Radiol · 2021-05-27

这项前瞻性研究纳入66例患者共83个肝细胞癌,比较钆塞酸二钠与钆贝葡胺在动态增强MRI前3分钟的动脉输入函数质量及肿瘤和肝实质灌注参数。两组动脉输入函数质量和肝细胞癌灌注参数相似,钆塞酸二钠组肝实质血流较低且强化较晚,但病灶-肝脏对比度无显著差异。

要点

  • 钆塞酸二钠与钆贝葡胺在肝细胞癌动态增强MRI中提供的动脉输入函数质量和肿瘤灌注参数相当。
  • 钆塞酸二钠组肝实质门脉血流和总血流较低、达峰时间和平均通过时间延长,但病灶-肝脏对比度无差异。
  • 两种对比剂在动态期肝细胞癌病灶检出和 conspicuity 方面可互换使用,但需注意肝实质强化时相差异。

关键影像表现/征象

  • 两组动脉输入函数质量、肝细胞癌的模型参数和无模型灌注参数相似(p=0.054-0.932)。
  • 钆塞酸二钠组肝实质血流较低且强化较晚(门静脉血流p=0.002;总血流p=0.001;达峰时间和平均通过时间均p<0.001)。
  • 两组肿瘤最大正性病灶-肝脏对比度比值(p=0.230)和最大负性病灶-肝脏对比度比值(p=0.317)无显著差异。

诊断标准与关键数值

  • 肝细胞癌灌注参数包括无模型参数达峰时间(TTP)和洗脱时间,以及模型参数动脉血流(Fa)、门静脉血流(Fp)、总血流(Ft)、动脉分数、平均通过时间(MTT)和分布容积(DV)。
  • 病灶-肝脏对比度比值(LLCR)测量最大正性和最大负性对比度比值,两组间无显著差异(p=0.230和p=0.317)。
  • 钆塞酸二钠组肝实质门静脉血流和总血流较低(p=0.002和p=0.001),达峰时间和平均通过时间延长(均p<0.001)。

局限性

  • 单中心前瞻性研究,样本量有限(66例患者83个病灶)。
  • 两组患者人群不同,非随机分配对比剂。
  • 仅评估注射后前3分钟的动态期,未涵盖肝胆期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: (1) To assess the quality of the arterial input function (AIF) during dynamic contrast-enhanced (DCE) MRI of the liver and (2) to quantify perfusion parameters of hepatocellular carcinoma (HCC) and liver parenchyma during the first 3 min post-contrast injection with DCE-MRI using gadoxetate disodium compared to gadobenate dimeglumine (Gd-BOPTA) in different patient populations.

METHODS: In this prospective study, we evaluated 66 patients with 83 HCCs who underwent DCE-MRI, using gadoxetate disodium (group 1, n = 28) or Gd-BOPTA (group 2, n = 38). AIF qualitative and quantitative features were assessed. Perfusion parameters (based on the initial 3 min post-contrast) were extracted in tumours and liver parenchyma, including model-free parameters (time-to-peak enhancement (TTP), time-to-washout) and modelled parameters (arterial flow (Fa), portal venous flow (Fp), total flow (Ft), arterial fraction, mean transit time (MTT), distribution volume (DV)). In addition, lesion-to-liver contrast ratios (LLCRs) were measured. Fisher's exact tests and Mann-Whitney U tests were used to compare the two groups.

RESULTS: AIF quality, modelled and model-free perfusion parameters in HCC were similar between the 2 groups (p = 0.054-0.932). Liver parenchymal flow was lower and liver enhancement occurred later in group 1 vs group 2 (Fp, p = 0.002; Ft, p = 0.001; TTP, MTT, all p < 0.001), while there were no significant differences in tumour LLCR (max. positive LLCR, p = 0.230; max. negative LLCR, p = 0.317).

CONCLUSION: Gadoxetate disodium provides comparable AIF quality and HCC perfusion parameters compared to Gd-BOPTA during dynamic phases. Despite delayed and decreased liver enhancement with gadoxetate disodium, LLCRs were equivalent between contrast agents, indicating similar tumour conspicuity.

KEY POINTS: • Arterial input function quality, modelled, and model-free dynamic parameters measured in hepatocellular carcinoma are similar in patients receiving gadoxetate disodium or gadobenate dimeglumine during the first 3 min post injection. • Gadoxetate disodium and gadobenate dimeglumine show similar lesion-to-liver contrast ratios during dynamic phases in patients with HCC. • There is lower portal and lower total hepatic flow and longer hepatic mean transit time and time-to-peak with gadoxetate disodium compared to gadobenate dimeglumine.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Stocker D, Hectors S, Bane O, et al. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine. Eur Radiol. 2021. PMID: 34043055. doi:10.1007/s00330-021-08068-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。